Score is driven primarily by strong financial performance (growth, improving profitability, very low leverage, and improved cash flow), but is pulled down by very weak technicals (price below all major moving averages, negative MACD, and extremely oversold RSI/Stoch). Valuation is moderate with a modest dividend yield but a relatively higher P/E.
Positive Factors
Revenue and Margin Improvement
Sustained top-line growth combined with rising net margins indicates durable demand for Bharat Rasayan's technical agrochemical products and improving operational efficiency. This mix supports stronger recurring earnings, funds reinvestment into capacity or R&D, and underpins longer-term profitability.
Very Low Leverage and Strong Equity Base
Minimal leverage and a high equity ratio provide lasting financial flexibility, lowering solvency risk in a cyclical industry. The strong ROE shows efficient capital use, enabling the company to fund growth or weather downturns without relying on costly external financing.
Robust Cash Generation
Cash flow closely tracking accounting earnings demonstrates high quality of earnings and effective working-capital management. Strong free cash flow supports sustainable capex, potential dividends, and reduces dependence on external funding for strategic investments over the medium term.
Negative Factors
Negative EPS Growth
A sharp decline in EPS despite revenue gains signals earnings volatility or one-off pressures that impair retained earnings accumulation. Persistent EPS contraction can limit the firm's capacity to reinvest, pay dividends, or build reserves, weakening long-term financial resilience.
Exposure to Raw-Material Cost Volatility
Business economics depend on commodity inputs whose prices and availability can swing structurally. Sustained input-cost volatility compresses margins unless offset by pricing power or hedging, making profitability sensitive to external supply shocks over multiple quarters.
Limited Disclosed Revenue Visibility
Absence of disclosed long-term contracts or customer concentration details increases uncertainty around recurring revenue stability. Without visible offtake commitments, future volume and contract renewal risks are harder to assess, raising counterparty and demand-visibility risks over the medium term.
Bharat Rasayan Limited (BHARATRAS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹21.63B
Dividend Yield0.02%
Average Volume (3M)149.00
Price to Earnings (P/E)23.2
Beta (1Y)0.81
Revenue Growth6.39%
EPS Growth-15.53%
CountryIN
Employees816
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)24.08
Shares Outstanding16,621,073
10 Day Avg. Volume116
30 Day Avg. Volume149
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.89
Price to Sales (P/S)1.82
P/FCF Ratio16.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bharat Rasayan Limited Business Overview & Revenue Model
Company DescriptionBharat Rasayan Limited manufactures and sells technical grade pesticides, intermediates, and bulk formulations in India. It offers insecticides, herbicides, fungicides, and intermediates. The company also exports its products. Bharat Rasayan Limited was incorporated in 1989 and is headquartered in New Delhi, India.
How the Company Makes MoneyBharat Rasayan primarily makes money by manufacturing and selling agrochemical active ingredients (technical-grade pesticides/insecticides) and associated chemical intermediates. Revenue is generated through (1) sales of technical products to agrochemical formulators and other industry buyers who use these actives as inputs for branded and generic crop-protection formulations, and (2) sales of intermediates/contract manufacturing outputs where applicable, leveraging its chemical synthesis and plant capabilities. Earnings are influenced by product mix (higher-value actives vs. intermediates), volumes shipped to domestic customers and export buyers, and pricing linked to raw-material and solvent costs as well as global supply-demand dynamics for specific molecules. Specific disclosures on customer concentration, long-term offtake agreements, or named strategic partnerships are not available in the provided context and are therefore null.
Strong fundamentals: revenue grew 12.3% (2024 to 2025), margins improved (net margin up to 12.0%), leverage is very low (debt-to-equity 0.08), and cash generation strengthened (operating cash flow to net income 1.19; free cash flow to net income 0.97).
Income Statement
80
Positive
Bharat Rasayan has shown strong revenue growth, with a 12.3% increase from 2024 to 2025. Gross profit margin has remained robust at 33.8% in 2025. The net profit margin improved significantly to 12.0% in 2025, indicating effective cost management. Both EBIT and EBITDA margins have improved, suggesting enhanced operational efficiency.
Balance Sheet
75
Positive
The company maintains a healthy financial position with a low debt-to-equity ratio of 0.08 in 2025, signaling minimal leverage risk. Return on Equity is strong at 12.5%, reflecting effective use of equity. The equity ratio is impressive at 80.3%, indicating financial stability and a solid asset base.
Cash Flow
70
Positive
Operating cash flow has improved significantly, aligning well with net income, resulting in a healthy operating cash flow to net income ratio of 1.19. Free cash flow saw remarkable growth, indicating strong cash generation capabilities. Free cash flow to net income ratio stands at 0.97, showing effective cash management.
Breakdown
TTM
Mar 2025
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Income Statement
Total Revenue
12.26B
11.73B
10.45B
12.34B
12.95B
10.80B
Gross Profit
3.90B
3.96B
3.24B
3.95B
3.69B
3.30B
EBITDA
2.06B
2.01B
1.38B
2.06B
2.66B
2.45B
Net Income
1.33B
1.41B
955.10M
1.25B
1.76B
1.64B
Balance Sheet
Total Assets
14.56B
14.08B
11.97B
10.74B
10.86B
9.08B
Cash, Cash Equivalents and Short-Term Investments
2.79B
2.86B
1.41B
485.96M
66.88M
1.39B
Total Debt
904.41M
852.19M
804.74M
279.37M
1.74B
584.46M
Total Liabilities
2.59B
2.78B
2.10B
1.80B
3.16B
1.81B
Stockholders Equity
11.97B
11.30B
9.88B
8.93B
7.70B
7.27B
Cash Flow
Free Cash Flow
-161.72M
1.32B
140.26M
1.90B
-1.21B
1.40B
Operating Cash Flow
249.00K
1.68B
410.76M
2.13B
-654.55M
1.70B
Investing Cash Flow
-173.93M
-1.57B
-897.00M
-605.49M
511.36M
-1.53B
Financing Cash Flow
23.25M
41.22M
489.57M
-1.52B
-247.85M
-397.29M
Bharat Rasayan Limited Technical Analysis
Technical Analysis Sentiment
Negative
Last Price2201.25
Price Trends
50DMA
1728.48
Negative
100DMA
2138.72
Negative
200DMA
2356.78
Negative
Market Momentum
MACD
-133.62
Positive
RSI
24.94
Positive
STOCH
16.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BHARATRAS, the sentiment is Negative. The current price of 2201.25 is above the 20-day moving average (MA) of 1463.29, above the 50-day MA of 1728.48, and below the 200-day MA of 2356.78, indicating a bearish trend. The MACD of -133.62 indicates Positive momentum. The RSI at 24.94 is Positive, neither overbought nor oversold. The STOCH value of 16.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BHARATRAS.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 21, 2026